Market Place
Sourcing Support
Japan`s Shionogi says COVID treatment did not meet endpoint in late-stage trial
13 May 2024 //
REUTERS
Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness
11 Oct 2023 //
BUSINESSWIRE
Shionogi Presents New Ensitrelvir Clinical and Real-World Data
18 Sep 2023 //
BUSINESSWIRE
Seven manufacturers sign sublicence agreements with MPP to produce ensitrelvir
27 Jun 2023 //
INDIANPHARMAPOST
Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid
04 Apr 2023 //
BUSINESSWIRE
Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment
04 Apr 2023 //
BUSINESSWIRE
Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data
21 Feb 2023 //
BUSINESSWIRE
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
15 Feb 2023 //
BUSINESSWIRE
U.S. NIH starts trial for Shionogi`s COVID-19 pill
15 Feb 2023 //
REUTERS
Notice Regarding a License Agreement for the Promotion of Ensitrelvir
29 Dec 2022 //
SHIONOGI
Japanese government buys quantity of COVID-19 drug Xocova from Shionogi
13 Dec 2022 //
BIOSPECTRUMASIA
Xocova Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection
22 Nov 2022 //
PRESS RELEASE
Shionogi’s antiviral pill hits the mark
29 Sep 2022 //
PRESS RELEASE
S-217622 Shows High In Vitro Antiviral Activity Against Omicron Subvariants
10 Aug 2022 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.